Literature DB >> 9138102

Enzyme immunoassay to detect antituberculous glycolipid antigen (anti-TBGL antigen) antibodies in serum for diagnosis of tuberculosis.

M Kawamura1, N Sueshige, K Imayoshi, I Yano, R Maekura, H Kohno.   

Abstract

We report the development of an EIA specific for antituberculosis antibody in human serum for the clinical evaluation of tuberculosis. We developed a TLC immunostaining method to detect specific antigens for antibodies in the serum of patients with tuberculosis. The detected specific antigens, TDM and specific gylcolipid fraction, were individually purified from M. tuberculosis H37Rv by column chromatography. The two purified fractions were mixed and the mixture, termed TBGL antigen, was applied to an enzyme immunoassay suitable for the measurement of antituberculosis antibodies in serum. This EIA meets all the requirements of routine clinical assay in terms of sensitivity (detection limit: 0.125 U/ml), reproducibility (total CV : 3.3-6.0%), accuracy (recovery: 96-105%), simplicity and rapidity (< 2.5 h). Clinical validation of the assay was confirmed by the measurement of the anti-tuberculosis antibody in the serum of normal subjects and patients with pulmonary tuberculosis. The EIA tested in this study showed a high serodiagnostic discriminating power (90% sensitivity and 98% specificity).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9138102      PMCID: PMC6760682          DOI: 10.1002/(sici)1098-2825(1997)11:3<140::aid-jcla4>3.0.co;2-e

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  11 in total

1.  Specific serum agglutination of kaolin particles sensitized with tubercle phosphatide and its clinical evaluation as a serodiagnostic test for tuberculosis.

Authors:  Y TAKAHASHI
Journal:  Am Rev Respir Dis       Date:  1962-05

2.  [Evaluation of serodiagnosis detecting IgG antibodies against purified protein derivative and alpha antigen in patients with active pulmonary tuberculosis by enzyme-linked immunosorbent assay].

Authors:  N Kusano
Journal:  Kekkaku       Date:  1987-04

Review 3.  The serodiagnosis of tuberculosis and other mycobacterial diseases by enzyme-linked immunosorbent assay.

Authors:  T M Daniel; S M Debanne
Journal:  Am Rev Respir Dis       Date:  1987-05

Review 4.  Antibody and antigen detection for the immunodiagnosis of tuberculosis: why not? What more is needed? Where do we stand today?

Authors:  T M Daniel
Journal:  J Infect Dis       Date:  1988-10       Impact factor: 5.226

Review 5.  Enzyme-labeling of antibodies and their fragments for enzyme immunoassay and immunohistochemical staining.

Authors:  E Ishikawa; M Imagawa; S Hashida; S Yoshitake; Y Hamaguchi; T Ueno
Journal:  J Immunoassay       Date:  1983

6.  Antibody formation to trehalose-6,6'-dimycolate (cord factor) of Mycobacterium tuberculosis.

Authors:  M Kato
Journal:  Infect Immun       Date:  1972-02       Impact factor: 3.441

7.  Immunochemical properties of anti-cord factor antibody.

Authors:  M Kato
Journal:  Infect Immun       Date:  1973-01       Impact factor: 3.441

Review 8.  Tuberculosis: commentary on a reemergent killer.

Authors:  B R Bloom; C J Murray
Journal:  Science       Date:  1992-08-21       Impact factor: 47.728

9.  Serodiagnosis of tuberculosis using the enzyme-linked immunoabsorbent assay (ELISA) of antibody to Mycobacterium tuberculosis antigen 5.

Authors:  R G Benjamin; T M Daniel
Journal:  Am Rev Respir Dis       Date:  1982-12

10.  Monoclonal antibodies specific for 18-hydroxycortisol and their use in an enzyme immunoassay for human urinary 18-hydroxycortisol for diagnosis of primary aldosteronism.

Authors:  H Kohno; S Sato; H Chiba; K Kobayashi; S Ikegawa; T Kurosawa; M Tohma
Journal:  Clin Biochem       Date:  1994-08       Impact factor: 3.281

View more
  7 in total

1.  Prospective clinical evaluation of the serologic tuberculous glycolipid test in combination with the nucleic acid amplification test.

Authors:  Ryoji Maekura; Hiroaki Kohno; Atsushi Hirotani; Yoshinari Okuda; Masami Ito; Takeshi Ogura; Ikuya Yano
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

2.  Rapid serodiagnosis of active pulmonary Mycobacterium tuberculosis by analysis of results from multiple antigen-specific tests.

Authors:  Yoshinari Okuda; Ryoji Maekura; Atsusi Hirotani; Seigo Kitada; Kenji Yoshimura; Touru Hiraga; Yuoko Yamamoto; Masami Itou; Takeshi Ogura; Toshio Ogihara
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

3.  Clinical evaluation of anti-tuberculous glycolipid immunoglobulin G antibody assay for rapid serodiagnosis of pulmonary tuberculosis.

Authors:  R Maekura; Y Okuda; M Nakagawa; T Hiraga; S Yokota; M Ito; I Yano; H Kohno; M Wada; C Abe; T Toyoda; T Kishimoto; T Ogura
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

4.  Comparison of patients with ocular tuberculosis in the 1990s and the 2000s.

Authors:  Jun Suzuki; Keiko Oh-I; Takeshi Kezuka; Jun-Ichi Sakai; Hiroshi Goto
Journal:  Jpn J Ophthalmol       Date:  2010-02-12       Impact factor: 2.447

5.  Increased synthesis of anti-tuberculous glycolipid immunoglobulin G (IgG) and IgA with cavity formation in patients with pulmonary tuberculosis.

Authors:  Masako Mizusawa; Mizuoho Kawamura; Mikio Takamori; Tetsuya Kashiyama; Akira Fujita; Motoki Usuzawa; Hiroki Saitoh; Yugo Ashino; Ikuya Yano; Toshio Hattori
Journal:  Clin Vaccine Immunol       Date:  2008-01-09

6.  New synthetic lipid antigens for rapid serological diagnosis of tuberculosis.

Authors:  Alison Jones; Mark Pitts; Juma'a R Al Dulayymi; James Gibbons; Andrew Ramsay; Delia Goletti; Christopher D Gwenin; Mark S Baird
Journal:  PLoS One       Date:  2017-08-14       Impact factor: 3.240

7.  Comparison of antibody responses against Mycobacterium tuberculosis antigen Rv0679c in tuberculosis patients from the endemic and non-endemic regions of the Beijing genotype: a case control study.

Authors:  Jingge Zhao; Takashi Matsuba; Xiaoyan Zhang; Susan Leano; Chie Nakajima; Haorile Chagan-Yasutan; Elizabeth Freda Telan; Yasuhiko Suzuki; Toshio Hattori
Journal:  BMC Infect Dis       Date:  2017-05-15       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.